Genus (GNS)

Sector:

Pharma and Biotech

Index:

FTSE 250

0.000p
   
  • Closing Price Chg:
      35.00p
  • 52 Week High: 2,555.00
  • 52 Week Low: 1,424.00
  • Currency: UK Pounds
  • Shares Issued: 66.04m
  • Volume: 0
  • RiskGrade: 128

Financial Analysis

Select chart: EPS | Dividend | Revenue

Latest Interim/Quarterly

Period Ending Period Revenue (£m) Pre-tax (£m) EPS Dividend
31-Dec-24 Interim 336.40 3.30 39.80p 10.30p

Key Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-20 551.40 46.30 77.30p 45.7 7.6 +6% 29.10p 0.8%
30-Jun-21 574.30 55.80 100.90p 49.2 1.6 +30% 32.00p 0.6%
30-Jun-22 593.40 48.40 82.70p 30.3 n/a -18% 32.00p 1.3%
30-Jun-23 689.70 39.40 84.80p 25.5 12.8 +2% 32.00p 1.5%
30-Jun-24 668.80 5.50 65.50p 25.2 n/a -23% 32.00p 1.9%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-25 671.96 76.77 76.72p 32.9 1.9 +17% 32.84p 0.0%
30-Jun-26 699.01 87.08 89.20p 28.3 1.7 +16% 34.66p 0.0%
30-Jun-27 731.77 95.26 102.38p 24.7 1.7 +15% 36.87p 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

Price / Earnings Data

5 Yr High 5 Yr Low 5 Yr Avg Curr / Avg
Latest 45.69 25.19 35.18 1.10

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

Genus Market Data

Currency UK Pounds
Share Price 2,525.00p
Closing Price Change 35.00p
% Change 0.00 %
52 Week High 2,555.00
52 Week Low 1,424.00
Volume 0
Shares Issued 66.04m
RiskGrade 128

Genus Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.67% below the market average92.67% below the market average92.67% below the market average92.67% below the market average92.67% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
73.02% above the market average73.02% above the market average73.02% above the market average73.02% above the market average73.02% above the market average
95.56% above the sector average95.56% above the sector average95.56% above the sector average95.56% above the sector average95.56% above the sector average
Income
98.33% below the market average98.33% below the market average98.33% below the market average98.33% below the market average98.33% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
91.96% below the market average91.96% below the market average91.96% below the market average91.96% below the market average91.96% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

What The Brokers Say

Strong Buy 6
Buy 2
Neutral 0
Sell 1
Strong Sell 0
Total 9
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Genus Dividends

  Latest Previous
  Interim Final
Ex-Div 06-Mar-25 07-Nov-24
Paid 04-Apr-25 06-Dec-24
Amount 10.30p 21.70p

Trades for 05-Aug-2025

Time Volume / Share Price
15:00 26 @ 2,510.00p
15:00 18 @ 2,510.00p
14:57 171 @ 2,515.00p
14:57 188 @ 2,515.00p
14:51 600 @ 2,515.00p

Genus Key Personnel

CEO Jorgen Kokke
CFO Andy Russell

Top of Page